SELL-SIDE CONSENSUS - JULY 2025											
	2024 actuals		H1 2025 5 contributors			2025. 5 contributors			2026 5 contributors	2027 5 contributors	2028 4 contributors
	H1	FY	Average	Highest	Lowest	Average	Highest	Lowest	Average	Average	Average
Net Sales	448.7	911.9	438.4	448.7	428.4	897.6	911.9	881.7	852.0	886.7	927.8
Year on Year change	-9.6%	-10.0%	-2.3%	0.0%	-4.5%	-1.6%	0.0%	-3.3%	-5.1%	4.1%	3.7%
	0.0%	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Of which API Solutions	332.4	663.6	320.5	329.1	310.3	644.9	656.6	639.0	582.2	594.1	610.0
	-8.3%	-8.8%	-3.6%	-1.0%	-6.6%	-2.8%	-1.0%	-3.7%	-9.7%	2.0%	2.4%
- API Solutions - Other Clients	168.6	354.1	190.2	204.9	180.4	402.6	426.9	378.9	399.1	417.0	434.6
ADI Ostutione Osnefi	-0.7%	-1.7%	12.8%	21.5%	7.0%	13.7%	20.5%	7.0%	-1.1%	4.5%	3.9%
- API Solutions - Sanofi	163.7 -15.0%	309.5 -15.7%	130.3 -20.4%	141.1 -13.8%	105.4 -35.6%	242.3 -21.7%	264.4 -14.6%	219.6 -29.0%	183.1 -25.0%	177.2 -3.4%	175.4 -2.0%
	-13.0%	-13.770	-20.470	-13.870	-33.070	-21.770	-14.070	-29.0%	-23.076	-3.470	-2.070
Of which CDMO	116.4	248.3	117.9	127.2	109.2	252.7	268.6	242.6	269.8	292.6	317.8
	-13.3%	-13.1%	1.3%	9.3%	-6.2%	1.8%	8.2%	-2.3%	6.8%	8.5%	6.4%
- CDMO - Other Clients	72.3	135.6	61.7	83.1	38.8	125.3	155.9	83.5	135.0	150.1	169.8
	-12.7%	-24.9%	-14.7%	15.0%	-46.4%	-7.6%	15.0%	-38.5%	8.4%	11.2%	8.6%
- CDMO - Sanofi	44.1 -14.2%	112.7 7.0%	56.2 27.5%	77.3 75.4%	44.1 0.0%	127.4 13.0%	163.5 45.0%	112.7 0.0%	134.8 5.7%	142.5 5.6%	148.0 3.7%
	-14.2%	7.0%	27.5%	/5.4%	0.0%	13.0%	45.0%	0.0%	5.7%	5.6%	3.7%
Of which other clients	240.9	489.7	251.9	269.1	221.9	528.0	560.6	486.9	534.1	567.0	604.5
	-4.6%	-9.4%	4.6%	11.7%	-7.9%	7.8%	14.5%	-0.6%	0.9%	6.3%	5.4%
Of which Sanofi	207.8	422.2	186.5	206.5	164.9	369.7	416.7	335.8	317.9	319.7	323.4
	-14.9%	-10.7%	-10.3%	-0.6%	-20.6%	-12.4%	-1.3%	-20.5%	-14.4%	0.8%	1.0%
Other Revenues	2.2	7.3	1.3	2.3	0.0	3.0	7.7	0.0	3.1	3.2	4.0
GROSS PROFIT	98.0	142.4	75.7	80.1	70.2	149.9	164.0	126.6	151.0	169.2	176.8
GP Margin	21.8%	15.6%	17.3%	18.1%	15.9%	16.7%	18.1%	14.0%	17.8%	19.1%	19.1%
EBITDA	-1.4	-43.6	3.8	22.2	-1.4	22.5	54.3	-1.2	33.8	79.6	124.8
Restructuring costs	49.0	-94.0	38.5	49.7	32.5	56.8	72.0	20.0	56.5	35.5	0.0
CORE EBITDA	47.6	50.4	30.2	32.2	24.6	71.5	72.3	70.3	92.8	119.7	130.6
CORE EBITDA Margin	10.6%	5.5%	6.9%	7.3%	5.7%	8.0%	8.2%	7.7%	10.9%	13.5%	14.1%
Operating Income	-33.4	-120.4	-31.7	-9.4	-53.2	-56.0	-15.9	-75.9	-38.1	7.4	54.9
Finance revenues/costs	-8.1	-19.2	-10.6	-8.1	-12.9	-21.1	-15.2	-28.6	-22.9	-21.7	-20.6
Income before tax	-41.5	-139.6	-39.2	-22.2	-52.2	-77.8	-44.5	-102.0	-60.5	-13.5	34.3
Income tax Expense	6.7	9.0	4.2	6.7	1.9	6.4	9.5	4.3	9.3	1.8	-5.2
Net Income	-34.8	-130.6	-39.1	-17.5	-54.6	-72.3	-35.0	-100.4	-52.8	-11.8	29.1
Average number of shares(m)	94.3	0.0	95.2	95.9	94.5	95.0	95.6	94.5	95.0	95.0	94.8
EPS	-0.37	-1.38	-0.41	-0.18	-0.57	-0.76	-0.37	-1.05	-0.56	-0.12	0.31
CAPEX	61	108	48	48	48	96	100	88	85	87	85
UAFEA	61	108	48	48	48	96	100	68	85	87	85
Cash Flow before Financing	10	15				-21	13	-77	-15	-8	39

Forward-Looking Statements - The information above is a nonexhaustive summary of the estimates of the financial analysts covering Euroapi. These estimations have been compiled by Euroapi and are provided for information purposes only. The presence of this consensus on Euroapi website does not constitute validation or approval of the forecast presented, or of any element thereof, by Euroapi. This information is not and cannot be construed as an invitation or a recommendation to buy or sell securities or to conclude any transaction of any kind.